Use of Cefiderocol in the Management of Children With Infection or Colonization With Multi-drug Resistant Gram-negative Bacteria: A Retrospective, Single-center Case Series-Reference-Cited by-同舟云学术

Use of Cefiderocol in the Management of Children With Infection or Colonization With Multi-drug Resistant Gram-negative Bacteria: A Retrospective, Single-center Case Series

Published:2024-04-02 Issue:8 Volume:43 Page:772-776
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Schmid Hanna¹^ORCID,Brown Li-An K.²,Indrakumar Bairavi³,McGarrity Orlagh³^ORCID,Hatcher James²,Bamford Alasdair¹⁴

Affiliation:

1. Paediatric Infectious Diseases

2. Department of Microbiology, Laboratory Medicine

3. Pharmacy Department, Great Ormond Street Hospital for Children NHS Foundation Trust

4. Infection, Immunity & Inflammation Department, UCL Great Ormond Street Institute of Child Health, London, United Kingdom

Abstract

Cefiderocol, a novel siderophore cephalosporin, represents a treatment option for infections with multidrug-resistant Gram-negative bacteria, of which rates are rising worldwide. Clinical data on its use in children is limited. In our pediatric case series, the largest reported to date, cefiderocol seems safe and well tolerated, with more favorable clinical outcomes when compared to the literature reviewing adult cases.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference9 articles.

1. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.;Bassetti;Lancet Infect Dis,2021

2. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.;Wunderink;Lancet Infect Dis,2021

3. Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram-negative bacilli infections: a case series.;Hoellinger;Clin Microbiol Infect,2023

4. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant achromobacter species infection in a pediatric cystic fibrosis patient.;Gainey;Pediatr Pulmonol,2020

5. Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant pseudomonas aeruginosa and extended-spectrum-β-lactamase-producing klebsiella pneumoniae in a pediatric patient.;Alamarat;Antimicrob Agents Chemother,2020